Literature DB >> 8852943

Effects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats.

Y Tanaka1, T Nakamura, S Nishida, K Suzuki, S Takeda, K Sato, Y Nishii.   

Abstract

To determine the action of corticosteroid on bone metabolism and assess the effects of a synthetic vitamin D analog, ED-71, on them, 56 SD rats, 8 weeks of age, were assigned to seven groups of eight animals each. Group 1 was the basal control. Group 2 was the nontreated control. Groups 3-7 were given prednisolone at 30 mg/kg of body weight (BW) twice a week and concomitantly administered ED-71 with respective doses of 0, 0.0125, 0.025, 0.05, and 0.1 micrograms/kg of BW for 12 weeks. In group 3, urinary calcium (U-Ca) and deoxypyridinoline (U-Dpy) were significantly increased compared with group 2. In groups 4-7, U-Ca values were increased but U-Dpy values were dose-dependently decreased. Age-dependent increases in the parameter values of BMD, compressive strength, trabecular bone volume (BV/TV), and trabecular thickness (Tb.Th) of the lumbar body were significantly suppressed in group 3 but dose-dependently increased in groups 4-7, and the values of group 7 exceeded those of group 2. The parameters of bone mineral density (BMD) and the bending strength of the femur in groups 4-7 were larger than the values in group 3 but did not reach the levels of group 2. The trabecular bone formation rate (BFR/BS) of the lumbar body measured by calcein labeling in group 3 was reduced when compared with group 2, but the values were not further decreased in groups 4-7. The perimeter ratios of double labels over single labels (dLS/sLS) greatly decreased by prednisolone, were dose-dependently increased to the level of the normal control by ED-71. Double-labeled perimeters and the dLS/sLS ratios were also increased in the periosteal envelope of the midfemur. These findings clearly demonstrate that prednisolone administration affects the age-related changes in bone metabolism, and ED-71 administration counteracts the effects by increasing intestinal calcium absorption, reducing bone resorption, and enhancing mineralization. The action of ED-71, however, seems to be less potent in the cortical bone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852943     DOI: 10.1002/jbmr.5650110306

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  5 in total

Review 1.  The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).

Authors:  Luisella Cianferotti; Claudio Cricelli; John A Kanis; Ranuccio Nuti; Jean-Y Reginster; Johann D Ringe; Rene Rizzoli; Maria Luisa Brandi
Journal:  Endocrine       Date:  2015-05-01       Impact factor: 3.633

2.  Modulation of bone turnover by alfacalcidol and/or alendronate does not prevent glucocorticoid-induced osteoporosis in growing minipigs.

Authors:  Shojiro Akahoshi; Akinori Sakai; Shinobu Arita; Satoshi Ikeda; Yoshiomi Morishita; Hideki Tsutsumi; Masako Ito; Ayako Shiraishi; Toshitaka Nakamura
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

3.  Effect of ED-71, a New Active Vitamin D Analog, on Bone Formation in an Orthopedically Expanded Suture in Rats. A Histomorphometric Study.

Authors:  Tancan Uysal; Mihri Amasyali; Sukru Enhos; Mehmet Fatih Sonmez; Deniz Sagdic
Journal:  Eur J Dent       Date:  2009-07

4.  Comparison of the effect of vitamin K(2) and risedronate on trabecular bone in glucocorticoid-treated rats: a bone histomorphometry study.

Authors:  Jun Iwamoto; Hideo Matsumoto; Tsuyoshi Tadeda; Yoshihiro Sato; James K Yeh
Journal:  Yonsei Med J       Date:  2009-04-30       Impact factor: 2.759

Review 5.  Eldecalcitol for the treatment of osteoporosis.

Authors:  Yuko Noguchi; Hisaya Kawate; Masatoshi Nomura; Ryoichi Takayanagi
Journal:  Clin Interv Aging       Date:  2013-09-27       Impact factor: 4.458

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.